Image-guided focused ultrasound ablation of breast cancer: current status, challenges, and future directions.
Image-guided focused ultrasound ablation of breast cancer: current status, challenges, and future directions.
复制标题
乳腺癌的图像引导的集中超声消融：当前状态，挑战和未来方向。
DOI：
10.1007/s00330-008-0906-0
复制
发表时间：
2008-07
影响因子：
5.9
通讯作者：
van den Bosch, M. A. A. J.
中科院分区：
文献类型：
--
作者：
Schmitz, A. C.;Gianfelice, D.;Daniel, B. L.;Mali, W. P. Th. M.;van den Bosch, M. A. A. J.
图像引导聚焦超声（FUS）消融术是一种非侵入性手术，已被用于治疗良性或恶性乳腺肿瘤。消融过程中的图像引导可以通过实时超声（US）或磁共振成像（MRI）来实现。过去十年的I期研究已经证明，mri引导和us引导的乳腺癌FUS消融术在技术上是可行和安全的。我们提供了研究评估的有效性的研究综述，以肿瘤完全坏死的百分比来衡量FUS对乳腺肿瘤消融的疗效。消融成功率从20%到100%不等，取决于FUS系统类型、成像技术、消融方案和患者选择。本文提出了与乳腺癌的FUS消融相关的具体问题，如较大肿瘤的治疗时间延长，消融边缘的大小，FUS消融后用于边缘评估和残余肿瘤检测的方法，以及FUS消融对前哨淋巴结手术的影响。最后，讨论了FUS在乳腺癌治疗中的潜在应用，如FUS诱导的抗肿瘤免疫反应、FUS介导的基因转移和增强的药物传递。目前，保乳手术仍然是乳腺癌治疗的黄金标准。
Image-guided focussed ultrasound (FUS) ablation is a non-invasive procedure that has been used for treatment of benign or malignant breast tumours. Image-guidance during ablation is achieved either by using real-time ultrasound (US) or magnetic resonance imaging (MRI). The past decade phase I studies have proven MRI-guided and US-guided FUS ablation of breast cancer to be technically feasible and safe. We provide an overview of studies assessing the efficacy of FUS for breast tumour ablation as measured by percentages of complete tumour necrosis. Successful ablation ranged from 20% to 100%, depending on FUS system type, imaging technique, ablation protocol, and patient selection. Specific issues related to FUS ablation of breast cancer, such as increased treatment time for larger tumours, size of ablation margins, methods used for margin assessment and residual tumour detection after FUS ablation, and impact of FUS ablation on sentinel node procedure are presented. Finally, potential future applications of FUS for breast cancer treatment such as FUS-induced anti-tumour immune response, FUS-mediated gene transfer, and enhanced drug delivery are discussed. Currently, breast-conserving surgery remains the gold standard for breast cancer treatment.
登录
查看更多内容
DOI：
10.1016/j.jamcollsurg.2006.04.002
发表时间：
2006-07-01
影响因子：
5.2
作者：
Furusawa, H;Namba, K;Nakahara, H
通讯作者：
Nakahara, H
影响因子：
19.7
作者：
Goldberg, SN;Grassi, CJ;Silverman, SG
通讯作者：
Silverman, SG
影响因子：
5.5
作者：
Hynynen, K;Freund, WR;Jolesz, FA
通讯作者：
Jolesz, FA
影响因子：
19.7
作者：
Fornage, BD;Sneige, N;Singletary, SE
通讯作者：
Singletary, SE
影响因子：
3.8
作者：
Gianfelice, D;Khiat, A;Boulanger, Y
通讯作者：
Boulanger, Y